LifeTech Scientific (HKG:1302) said an aortic arch stent graft system obtained official registration approval from China's National Medical Products Administration, a Thursday Hong Kong bourse filing said.
The firm has independent intellectual property rights for the stent graft system, which was jointly developed by the company, the National Centre for Cardiovascular Diseases, Professor Shu Chang of Fuwai Hospital, and the Chinese Academy of Medical Sciences.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.